844903-58-8

Basic information

• Product Name: GSK163090
• Synonyms: GSK163090;1-[3-[2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl]phenyl]-2-imidazolidinone;2-Imidazolidinone,1-[3-[2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl]phenyl]-
• CAS NO: 844903-58-8
• Molecular Formula: C₂₅H₂₉N₅O
• Molecular Weight: 415.53066
• Mol File: 844903-58-8.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Density: 1.216±0.06 g/cm3(Predicted)
• PKA: 14.20±0.20(Predicted)
• CAS DataBase Reference: GSK163090(CAS DataBase Reference)
• NIST Chemistry Reference: GSK163090(844903-58-8)
• EPA Substance Registry System: GSK163090(844903-58-8)

Safety Data

• Hazardous Substances Data: 844903-58-8(Hazardous Substances Data)

Usage

General Description

GSK163090 is a chemical compound that has been the subject of research and study for its potential therapeutic effects in various medical conditions. It is a potent and selective antagonist of the tachykinin neurokinin 1 (NK1) receptor, which is involved in the regulation of pain and inflammation. Studies have shown that GSK163090 can effectively block the activation of NK1 receptors, leading to reduced pain sensitivity and inflammation. This makes it a promising candidate for the treatment of conditions such as chronic pain, migraine, and inflammatory diseases. Additionally, GSK163090 has also been investigated for its potential use in the management of substance abuse and addiction, as the NK1 receptor is involved in the reward and reinforcement pathways in the brain. Further research and clinical trials are needed to fully understand the potential of GSK163090 in treating these various conditions.

Upstream product

• 844903-55-5 1-[3-(2-hydroxyethyl)phenyl]-2-imidazolidinone 
• 1338431-75-6 C₂₅H₂₇N₅O₂ 
• 698981-81-6 2-methyl-5-(1-piperazinyl)quinoline 
• 844903-56-6 2-[3-(2-oxo-1-imidazolidinyl)phenyl]ethyl methanesulfonate 

Downstream Products

• 844903-52-2 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone dihydrochloride 

Relevant articles and documents

Application of the quality by design principles for the development of the crystallization process for a piperazinyl-quinoline and definition of the control strategy for form 1

The studies carried out to develop a robust crystallization method for the substituted piperazinyl-quinoline (1) a compound potentially active in the treatment of depression, are described in this contribution. These studies include the control of a solva

Discovery of 1-(3-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl) -2-imidazolidinone (GSK163090), a potent, selective, and orally active 5-HT 1A/B/D receptor antagonist

In an effort to identify selective drug like pan-antagonists of the 5-HT1 autoreceptors, studies were conducted to elaborate a previously reported dual acting 5-HT1 antagonist/SSRI structure. A novel series of compounds was identifie